Synonym
SI-12; SI12; SI 12
IUPAC/Chemical Name
(E)-5,6-difluoro-2-(((E)-1-(5-fluoropyridin-2-yl)ethylidene)hydrazineylidene)-1-methyl-2,3-dihydro-1H-benzo[d]imidazole
InChi Key
QPBNFTTUAKVEKN-ODCIPOBUSA-N
InChi Code
InChI=1S/C15H12F3N5/c1-8(12-4-3-9(16)7-19-12)21-22-15-20-13-5-10(17)11(18)6-14(13)23(15)2/h3-7H,1-2H3,(H,20,22)/b21-8+
SMILES Code
FC1=C(F)C=C(N/2[H])C(N(C)C2=N\N=C(C)\C3=NC=C(F)C=C3)=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
319.29
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Qin L, Chen J, Lu D, Jain P, Yu Y, Cardenas D, Peng X, Yu X, Xu J, Wang J,
O'Malley BW, Lonard DM. Development of improved SRC-3 inhibitors as breast
cancer therapeutic agents. Endocr Relat Cancer. 2021 Aug 13;28(10):657-670. doi:
10.1530/ERC-20-0402. PMID: 34310341; PMCID: PMC8404148.
2: Bijou I, Liu Y, Lu D, Chen J, Sloan S, Alinari L, Lonard DM, O'Malley BW,
Wang M, Wang J. Inhibition of SRC-3 as a potential therapeutic strategy for
aggressive mantle cell lymphoma. Res Sq [Preprint]. 2023 Mar 10:rs.3.rs-2653461.
doi: 10.21203/rs.3.rs-2653461/v1. PMID: 36945511; PMCID: PMC10029087.
3: Lu D, Chen J, Qin L, Bijou I, Yi P, Li F, Song X, MacKenzie KR, Yu X, Yang B,
Roy Chowdhury S, Korp JD, O'Malley BW, Lonard DM, Wang J. Lead Compound
Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and
Anticancer Efficacy. J Med Chem. 2024 Mar 29. doi: 10.1021/acs.jmedchem.3c01596.
Epub ahead of print. PMID: 38551814.